GWPRF - GW Pharmaceuticals plc

Other OTC - Other OTC Delayed Price. Currency in USD
14.40
-0.50 (-3.36%)
At close: 1:47PM EDT
Stock chart is not supported by your current browser
Previous Close14.90
Open14.38
Bid0.00 x 0
Ask0.00 x 0
Day's Range14.38 - 14.95
52 Week Range7.07 - 16.00
Volume1,829
Avg. Volume5,028
Market Cap409.562M
Beta (3Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)-8.61
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cramer goes off the charts to get a deeper look at cannabis stocks
    CNBC Videos25 days ago

    Cramer goes off the charts to get a deeper look at cannabis stocks

    Jim Cramer takes a look at his colleague and technician Tim Collins' interpretation of the cannabis sector.

  • GW Pharmaceuticals (GWPH) Should Find a Place in Your Portfolio
    SmarterAnalyst2 days ago

    GW Pharmaceuticals (GWPH) Should Find a Place in Your Portfolio

    June has been one roller coaster ride for cannabis stocks. First, the FDA reported that CBD be treated like a drug causing cannabis stocks to decline, then a slurry of upgrades caused some cannabis stocks to soar and now the whole industry is rebounding with overall good investor sentiment.Honestly, no surprises for such a volatile industry. This volatility, surprising last-minute news and enormous swings are nothing new for cannabis stocks. Although one stock was particularly interesting. When the FDA reported its ‘findings’ for CBD, GW Pharmaceuticals (GWPH) seemed to explode.From a technical standpoint, GWPH is a very interesting stock. Unlike most of the industry, GWPH is trending positively beyond any normal cannabis stock consolidation. In fact, the stock is looking more like an incredibly bullish long-term buy. Why is GW Pharmaceuticals so interesting? First of all, after the FDA’s ruling on CBD, GWPH stock jumped. Why? Because the company owns one of the only CBD products approved by the FDA for treatment of both childhood-onset forms of epilepsy. The drug itself is called Epidiolex and you’ll be hearing a lot about it in the weeks to come. Having close ties with the FDA is a really good asset to have. Although letting companies have free reign over CBD would be good for everyone, the government is still in charge of consumer safety. Federal bodies like the FDA won’t just back down from controlling weed products or CBD. It’s still going to be a tax, health and legal issue. So don’t expect the FDA to just wipe its hands clean and forgive or forget CBD products.Another important factor is that GW Pharmaceuticals is neither a Canadian or American company. It’s located and licensed in United Kingdom. Why is important? Because the European market is an incredibly valuable future marketplace for many big producers including Canopy and Aurora. Having a stationed and licensed cannabis company in any European country makes it an incredibly valuable proposition for investors. Companies like GW Pharmaceuticals will build resistance within their governments to prevent larger cannabis companies from simply setting up shop in their markets. Depending on how Brexit plays out, the final deal with the EU might either boost GW Pharmaceuticals or restrict its access to Europe. But most likely, some type of free trade agreement will exist between EU states and United Kingdom since trade is such an incredibly valuable part of Europe. Additional, European sentiment towards pot is positive. Most European countries are fairly libral when it comes to legalization and taxation of weed. Remember, pot was legal in parts or Europe way before North America.For investors, GW Pharmaceuticals looks like a great stock. The company itself reported better than expected sales for Epidiolex and announced recently positive results from its phase 3 study of the drug treating another rare type of epilepsy. And overall its been on a run and consolidating in a tight range upwards. It’s also a great stock to diversify away from strictly American and Canadian cannabis market. Looks like a great investment for the future of global cannabis.Analysts seem to agree. The cannabis player stands as a 'Strong Buy' name among Wall Street analysts, according to TipRanks. In the last three months, GWPH has won 10 bullish 'buy' recommendations. With a return potential of nearly 23%, the stock's consensus price target lands at $219.56.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Read more on GWPH: * Medicinal Cannabis Stock GW Pharmaceuticals Could Run Much Higher Over Time * Analysts Have Chosen: GWPH, APHA and CGC Are Top Cannabis Stock Picks More recent articles from Smarter Analyst: * Village Farms (VFF) Has a Lot Going for It * Hexo Has Difficult Days Ahead, Analyst Says * Square (SQ) Growth Slowing, But Evercore Remains Bullish on the Stock * This Analyst Sticks with His Buy Rating on Aphria (APHA) Stock, But Trims Price Target

  • The FDA Hearing on CBD Is Really Much Ado About Nothing
    Motley Fool7 days ago

    The FDA Hearing on CBD Is Really Much Ado About Nothing

    No matter what the FDA decides with regard to cannabidiol as a food or beverage additive, it'll have little bearing on consumers or investors.

  • 3 Top Marijuana Stocks to Watch in June
    Motley Fool7 days ago

    3 Top Marijuana Stocks to Watch in June

    With the industry possibly cooling off, here are the names to remember.

  • Here's What Last Week's FDA CBD Hearing Really Means for Cannabis Stocks
    Motley Fool11 days ago

    Here's What Last Week's FDA CBD Hearing Really Means for Cannabis Stocks

    The bottom line: a whole lot of uncertainty.

  • Investing in Marijuana Stocks: Everything You Need to Know
    Motley Fool15 days ago

    Investing in Marijuana Stocks: Everything You Need to Know

    Should you put your hard-earned money into these stocks? We detail the investment opportunities, the risks, and regulations in the cannabis space.

  • 3 ‘Strong Buy’ Cannabis Biotech Stocks To Know Now
    TipRanks18 days ago

    3 ‘Strong Buy’ Cannabis Biotech Stocks To Know Now

    If you are looking to invest in cannabis stocks, you may want to take a closer look at cannabis biotechs in particular. Several cannabis biotech firms are generating significant Street support- and for good reason as you will see below. To pinpoint the most compelling cannabis biotech stocks out there, we used TipRanks' data to pull up relevant biotechs with a 'Strong Buy' Street consensus. That's based on all the ratings received from analysts over the last three months. In fact, all these three stocks actually score 100% Street support- so no hold or sell ratings here. Let's take a closer look now at which 3 stocks make the grade, and why: GW Pharmaceuticals (GWPH – Research Report)British-based biopharma GWPH is one of the more well-known cannabis biotech stocks. Shares have put on a remarkable sprint for the beginning of 2019. Year-to-date we are now looking at gains of 88%. And the company’s recent earnings report indicates that plenty of growth lies ahead. In June 2018, the company’s lead cannabinoid drug Epidiolex received FDA approval for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. Following DEA re-scheduling, Epidiolex was launched on November 1.So far the launch has proved a remarkable success. For the first quarter, GW reported $33.5MM in Epidiolex revenue during its first full quarter on the market, well ahead of consensus ($15.9MM). But even more importantly, the company also revealed positive trial data for tuberous sclerosis complex (TSC). Specifically, GW announced that Epidiolex's Phase III trial in patients with seizures associated with tuberous sclerosis complex (TSC) met its primary endpoint with a high degree of statistical significance.The primary endpoint was the percent change from baseline in seizure frequency during the treatment period. At baseline, enrolled patients (average age of 14 years old) experienced a median of 57 seizures per month. After 16 weeks of treatment, patients in the 25 mg/kg/day cohort experienced an impressive 48.6% reduction in seizures relative to baseline.“1Q Snapshot \- A Strong Launch and Positive TSC Data Rolled Into a Joint Announcement for a Double Dose of Good News” cheered JP Morgan’s Cory Kasimov following the report. The analyst continued: “We’re not sure how GWPH’s 1Q19 report could have gone much better with Epidiolex doubling consensus in its first full quarter of sales… only to be one-upped by concurrent positive Phase 3 data in TSC.”As a result he believes Epidiolex is on track to come in north of $150M in its first full year, easily exceeding Street expectations. “The bottom line is that estimates need to come up, perhaps meaningfully. Furthermore, with another positive – and clean – phase 3 dataset in hand, there could be upward bias to longer term off label epilepsy sales, which offers a major upside lever in our model” concludes Kasimov. He reiterated his buy rating while ramping up his price target from $180 to $215. Unsurprisingly, he wasn’t the only analyst singing GWPH’s praises. “Based on Epidiolex's trajectory and the positive TSC data today we are increasing our DCF-based price target from $175 to $200. We continue to think that GW is undervalued” commented Cowen & Co’s Phil Nadeau. At the same time Oppenheimer’s Esther Rajavelu took a step further by upgrading GWPH from Hold to Buy. She also upped her price target from $164 to a Street-high $234 (27% upside). “While we await detailed data that may be shared at a medical conference, we update our probability of approval of the sNDA [supplemental new drug application] for TSC to 87% from 41% (filing expected in 4Q)” she explained. Overall GWPH has a very bullish outlook from the Street, with ten analysts publishing recent buy ratings on the stock. Their average analyst price target stands at $220- indicating upside potential of 20%. View GWPH Price Target & Analyst Ratings Detail Zynerba Pharmaceuticals Inc (ZYNE – Research Report)Zynerba is developing next-generation cannabinoid gels to help treat patients affected by rare neuropsychiatric conditions. The company is generating a significant buzz, with shares exploding over 340% year-to-date! So what’s behind the stock’s meteoric rise?Its lead drug candidate Zygel is a unique permeation-enhanced CBD transdermal gel. By delivering drugs through the skin and directly into the circulatory system, Zygel offers several advantages over oral medication. Most notably, transdermal delivery results in fewer gastrointestinal side effects, and avoidance of first-pass liver metabolism. This potentially enables lower dosage levels of active pharmaceutical ingredients and rapid, reliable absorption. Encouragingly, Zynerba announced earlier this month that the FDA has granted a Fast Track designation on Zygel for the treatment of behavioral problems associated with Fragile X syndrome (FXS). “With this designation, the company gains easier access to the FDA throughout the development process and most importantly, in our view, eligibility for Priority Review, which shortens the review time to six months” explains Ladenburg’s Michael Higgins. He anticipates Zygel’s NDA (new drug application filing) will take place in 1H20, leading to approval in 2H20. And with an eye on the future, Higgins reiterates his buy rating on ZYNE with a $26 price target (97% upside potential). While data since the summer of 2018 has been light, multiple major data readouts are comping up near-term- generating the recent rally in prices. “We continue to believe the stock could still double from its current level, driven by a data-rich 2H’19” the analyst tells investors. Upcoming data readouts include Phase 2 data from BELIEVE 1, evaluating Zygel’s anti-epileptic activity, and data from the FXS pivotal CONNECT-FX trail. “Given the unprecedented, profound and sustained benefits across multiple behavioral problems in the open-label Phase 2 (FAB-C), plus Zygel’s good tolerability, we again expect this trial to be successful” writes Higgins. Plus the catalysts should continue into 1H20 when data is expected for two new indications (autism spectrum disorder (ASD) and 22q11.2 deletion syndrome). Analysts are clearly feeling the heat- this is a stock with five recent back-to-back buy ratings and an average analyst price target of $23 (79% upside potential). View ZYNE Price Target & Analyst Ratings Detail Cara Therapeutics Inc (CARA – Research Report)Cara Therapeutics is a biotech focusing on developing products for better pruritus (i.e. severe itching- one of the most common dermatological complaints) and pain management. Right now, all eyes are squarely set on the imminent US Phase 3 data for IV Korsuva. This is Cara’s novel kappa opioid receptor agonist to treat chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients- where there is currently no effective treatment and minimal competitive development.Indeed top-rated Cantor Fitzgerald analyst Charles Duncan has just hosted a call with a key opinion leader (KOL) to discuss the outlook for Korsuva. In this case the KOL is a physician with expertise in chronic kidney disease associated pruritus (CKD-aP), making his insights particularly valuable. Overall, the KOL stated that, in his 25 years as a practicing nephrologist, he has seen little in drug development move the needle in CKD-aP (except the P2 data from KORSUVA), underscoring the need for new medications.“As a result of this recent due diligence, we have enhanced conviction about the P3 study readouts and potential for KORSUVA to usher-in a paradigm shift and a new SoC [standard of care] for this high-burden symptom of disease” Duncan concluded. He expects the data readout to come early June, and is upbeat about the drug's prospects. “We remain confident in positive results based on statistically significant Phase 2b results with much lower powering and shorter treatment duration” the analyst tells investors. Meanwhile, the second global Phase 3, KALM-2, is enrolling and management expects data in “2H19” (i.e. around 4Q). "Assuming KALM-1 is positive, we’ll also be optimistic for KALM-2", says the analyst. He reiterated his buy rating with a $27 price target, writing ‘Now is the time to scratch the itch.’ Given the stock is currently only trading at $18, the price target translates into sizable upside potential of over 50%. Bear in mind shares are already soaring 39% year-to-date. As we can see here, that's on top of six recent buy ratings from the Street:View CARA Price Target & Analyst Ratings Detail Enjoy Research Reports on the Stocks in this Article:Cara Therapeutics Inc (CARA) Research ReportGW Pharmaceuticals (GWPH) Research ReportZynerba Pharmaceuticals Inc (ZYNE) Research Report

  • Comparing GW Pharmaceuticals’ Returns to Peers
    Market Realist22 days ago

    Comparing GW Pharmaceuticals’ Returns to Peers

    Comparing GW Pharmaceuticals’ Returns to PeersGW PharmaceuticalsGW Pharmaceuticals (GWHP) is primarily into the development of cannabis-derived prescription medicines. Liquid cannabidiol (or CBD) is the leading product in the company’s

  • GW Pharmaceuticals (GWPH) Stock Could Run Much Higher Over Time
    SmarterAnalyst22 days ago

    GW Pharmaceuticals (GWPH) Stock Could Run Much Higher Over Time

    GW Pharmaceuticals (GWPH) has recently bounced after a solid earnings report. It also announced its phase-3 trial concerning its Epidiolex oral medicine, received positive results.The combination of the earnings beat and forward movement of Epidiolex, provide catalysts that should continue to drive GWPH stock price higher.The CatalystsRevenue in the latest reporting period ended March 31, 2019 came in at $39.2 million, far above the $3 million in revenue generated in the same reporting period of 2018, beating estimates by $23.33 million.Earnings for the quarter improved to a loss of $50.1 million, against the loss of $69.5 million year-over-year. Earnings per share was $-0.14, beating estimates by $0.07.Cash and cash equivalents fell from $591.5 million at the end of calendar year 2018, to $521.7 million at the end of the quarter.The second catalyst was the report of the company reaching another "primary efficacy measure with both EPIDIOLEX doses as compared to placebo." That was the "consecutive positive Phase 3 pivotal trial for EPIDIOLEX." The company is expected to file an sNDA in the fourth quarter of 2019.Net sales of Epidiolex in the quarter was $33.5 million, accounting for the majority of the revenue.Things to Consider for Current ShareholdersThere are a couple of important things to take into consideration with existing shareholders, including its share price and whether or not it can break out from its recent new highs.With its improvement with revenue and earnings, and its consistent positive news about Epidiolex, it would take a significant negative catalyst to reverse the sentiment in regard to the company, which suggests it may still have a lot of upward trajectory left.For that reason, unless shareholders want to take some profits off the table, it appears to be a low-risk play to maintain a position because the share price has a lot more room to run.Thoughts on Investors Looking to Take a Position in GWPHInvestors wanting to move quickly in and out of the stock would do better to wait to see if it drops below the recent breakout line before taking a position. Being a volatile stock, it would be best to wait for it to pull back and play the bounce if it comes.Spending is of particular concern, as the company projected operating expenses in a range of $395 million to $425 million for full-year 2019. It's almost certain that sales won't be able to cover those costs.The good news is at the end of the quarter the company had $521.7 million in cash, along with an additional $105 million it received from the sale of a review voucher in April.Even with rapidly growing revenue, increasing insurance coverage of the treatment, and its success in clinical trials, the company will continue to struggle to generate a profit in the near term. For that reason, investors wanting a stronger risk/reward metric, will probably stay away until the company shows it can generate a profit.One significant event that could be a powerful catalyst for GW Pharmaceuticals is if an European advisory committee gives approval this quarter for Epidiolex. If that's how it's plays out, patients with LGS and Dravet syndrome will have access to the treatment, providing a major boost in sales, and a  quicker path to profitability; there already is pricing and reimbursement in place in key European markets Germany and France.With all the expansion and additional costs, management believes the $521.7 million in cash and cash equivalents should be enough to cover the next 12 months.ConclusionGW Pharmaceuticals continues to prove it has a lot going for it, with it continuing to grow Epidiolex revenue, expand its footprint, and lowering costs while it's doing so.Both revenue, earnings and Epidiolex are all moving in the right direction together, and that provides a bullish scenario that should continue to support and push up the share price of the company, even though I suspect there will be a correction in the near future after its share price has almost doubled so far in 2019.For long-term holders, it will be a chance to add more to your position and lower your cost basis.As the company stands today, I think the long-term opportunity outweighs the short-term, because of the price support and accompanying contracting price range the company will trade in on a daily basis when it's volatile.If you believe in GW and are in it for the long haul, there's really not much to do but hold on to your shares and ride the upward wave. I would be patient if you want to add to your position, waiting for the inevitable pullback.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Read more on GWPH: * Analysts Have Chosen: GWPH, APHA and CGC Are Top Cannabis Stock Picks * GW Pharmaceuticals (GWPH): A “Blue Chip” Cannabis Stock to Watch More recent articles from Smarter Analyst: * Village Farms (VFF) Has a Lot Going for It * Hexo Has Difficult Days Ahead, Analyst Says * Square (SQ) Growth Slowing, But Evercore Remains Bullish on the Stock * This Analyst Sticks with His Buy Rating on Aphria (APHA) Stock, But Trims Price Target

  • The Smartest People on Wall Street Are Buying These 3 Stocks -- Should You Follow?
    Motley Foollast month

    The Smartest People on Wall Street Are Buying These 3 Stocks -- Should You Follow?

    Why are billionaire investors betting on stocks like Disney and GW Pharmaceuticals?

  • Benzingalast month

    The Week In Cannabis: A&F Tries CBD, GW Pharma Soars On Results, Denver Decriminalizes Mushrooms

    The cannabis world had an unlikely protagonist: magic mushrooms . After a popular vote, the city of Denver, Colorado, known as a legal cannabis trailblazer, approved a ballot measure to decriminalize psychedelic ...

  • Marijuana Stocks: 5 Facts You Need to Know About GW Pharmaceuticals Quarterly Results
    Motley Foollast month

    Marijuana Stocks: 5 Facts You Need to Know About GW Pharmaceuticals Quarterly Results

    GW Pharmaceuticals reported surging sales last quarter, but investors ought to be aware of a lot more than that.

  • Benzingalast month

    The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) BioSig Technologies ...

  • Marijuana Medicine: GW Pharmaceuticals Market Opportunity Could Double
    Motley Foollast month

    Marijuana Medicine: GW Pharmaceuticals Market Opportunity Could Double

    This drugmaker's cannabidiol formulation could become more widely used following positive phase 3 trial results in tuberous sclerosis complex.

  • Benzingalast month

    Analysts Raise Price Targets On GW Pharma's Positive Earnings, Epidiolex Results

    GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH ) opened higher by 8 percent Tuesday after posting positive results from its Phase 3 Epidiolex trial and second-quarter earnings beats. Here’s what analysts are ...

  • Benzingalast month

    GW Pharma's CBD Drug Epidiolex Could Secure Label Expansion Following Positive Trial Results

    GW Pharma reported Monday after the close with positive topline results from a Phase 3 study of Epidiolex in the treatment of seizures associated with tuberculosis sclerosis complex, or TSC. TSC is a rare genetic condition that causes tumors in different body organs, most often in the brain, skin, heart, eyes, kidneys and lungs, causing a variety of health problems.

  • Benzingalast month

    The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 6) Axsome Therapeutics Inc (NASDAQ: AXSM ) (FDA agreed to ...

  • Biotech Stock Pops After Cannabis Medicine Outsells Expectations
    Investor's Business Dailylast month

    Biotech Stock Pops After Cannabis Medicine Outsells Expectations

    GW stock popped late Monday after the biotech's first-quarter sales beat estimates. GW also said cannabis medicine Epidiolex succeeded in a test of patients with tuberous sclerosis complex.

  • Reuterslast month

    GW Pharma's epilepsy drug meets main goal in late-stage trial

    GW Pharmaceuticals Plc said on Monday its drug Epidiolex was successful in treating seizures in patients with a rare form of childhood epilepsy called tuberous sclerosis complex during a late-stage trial. In June, the drug became the first cannabis-based medicine to be approved in the United States after regulators permitted the treatment for two other forms of childhood epilepsy. The trial tested two doses of the drug against a placebo in treatment-resistant tuberous sclerosis complex (TSC) patients aged between 1 and 65.

  • Benzingalast month

    GW Pharmaceuticals Q2 Earnings Preview

    GW Pharmaceuticals (NASDAQ: GWPH ) will be releasing its next round of earnings this Monday, May 6. For all of the relevant information, here is your guide for Monday's second-quarter earnings announcement. ...

  • These 5 Pot Stocks Have the Most Cash
    Motley Foollast month

    These 5 Pot Stocks Have the Most Cash

    Two marijuana stocks currently have at least $1.8 billion in cash and cash equivalents at their disposal.

  • Benzingalast month

    Edison Research Sees $140B Potential In Cannabis

    Medical cannabis is a potential $140-billion market that's "being unlocked as the global march towards legalization continues," according to the market research firm Edison.  A Question Of When, ...

  • 3 of the Biggest Pot Stocks Have a Lot to Prove
    Motley Foollast month

    3 of the Biggest Pot Stocks Have a Lot to Prove

    These $5 billion-plus market cap marijuana stocks may not live up to the hype surrounding them.

  • Benzingalast month

    5 Biotech Stocks With Near-Term Catalysts Ahead

    The biotechnology space is an exciting one with incredible potential for investors. One strategy that many have found success with in the biotech investing space is making moves around catalysts. This involves looking for companies with data readouts, PDUFA dates, and other upcoming releases that will likely move the needle for the stock.

  • Ups and Downs in the Cannabis Space Last Week
    Market Realist2 months ago

    Ups and Downs in the Cannabis Space Last Week

    Cannabis Updates: Price Action, Ratings, and MoreCannabis spaceThe cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively, while the